株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

眼科治療薬市場分析:クラス別(抗アレルギー薬、抗VEGF薬、抗炎症薬、抗緑内障薬)、疾患別(ドライアイ、アレルギー、緑内障、感染、網膜疾患、ブドウ膜炎)、およびセグメント予測

Ophthalmic Therapeutics/Drug Market Analysis By Class (Anti-allergy, Anti-VEGF Agents, Anti-inflammatory, Anti-glaucoma), By Disease (Dry Eye, Allergies, Glaucoma, Infection, Retinal Disorders, Uveitis), And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 582047
出版日 ページ情報 英文 58 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
眼科治療薬市場分析:クラス別(抗アレルギー薬、抗VEGF薬、抗炎症薬、抗緑内障薬)、疾患別(ドライアイ、アレルギー、緑内障、感染、網膜疾患、ブドウ膜炎)、およびセグメント予測 Ophthalmic Therapeutics/Drug Market Analysis By Class (Anti-allergy, Anti-VEGF Agents, Anti-inflammatory, Anti-glaucoma), By Disease (Dry Eye, Allergies, Glaucoma, Infection, Retinal Disorders, Uveitis), And Segment Forecasts, 2014 - 2025
出版日: 2017年10月27日 ページ情報: 英文 58 Pages
概要

当レポートでは、世界の眼科治療薬市場について調査し、市場の概要とクラス別、疾患別、剤形別、製品別、および地域別の動向、市場に参入する企業のプロファイルなどをまとめています。

第1章 調査方法と調査範囲

第2章 エグゼクティブサマリー

第3章 市場の変動、動向、範囲

  • 市場セグメンテーションと範囲
    • 市場促進因子
    • 市場阻害因子
  • 浸透および成長見通しマッピング
  • SWOT分析
  • 業界分析:ポーターズ

第4章 薬剤クラス別予測と動向分析

  • 動向分析
  • 抗アレルギー薬
  • 抗VEGF薬
  • 抗炎症薬
  • 抗緑内障薬
  • その他

第5章 疾患別予測と動向分析

  • 動向分析
  • ドライアイ
  • アレルギー
  • 緑内障
  • 炎症/感染
  • 網膜疾患
  • ブドウ膜炎
  • その他

第6章 剤形別予測と動向分析

  • 動向分析
  • ゲル
  • 溶剤
  • カプセル・タブレット
  • 目薬
  • 軟膏

第7章 製品別予測と動向分析

  • 動向分析
  • 処方薬
  • OTC薬
  • 近年の薬剤承認

第8章 地域別予測と動向分析

  • 地域別市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合環境

  • 戦略的枠組み
  • 市場参入分類
  • 企業プロファイル
目次
Product Code: GVR-2-68038-010-1

The global ophthalmic therapeutics/drugs market is expected to reach USD 35.7 billion by 2025, according to a new report by Grand View Research, Inc. Increase in funding by public and private bodies for conducting research on ocular disorders with the presence of strong emerging pipeline drugs are some of the factors responsible for the growth of ophthalmic therapeutics market. For instance, the recent approval of Zerviate (cetirizine) for the treatment of allergic conjunctivitis in 2017 and Humira (adalimumab) and Xiidra (lifitegrast) in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth.

Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics are expected to provide this market with lucrative growth opportunities. In the recent years, a number of highly-effective and safe agents have emerged for the treatment of fungal ophthalmic diseases. Natamycin, amphotericin B, clotrimazole, are some of the most promising therapeutics present in the market. For instance, in October 2016, Santen Pharmaceuticals, Foundation for Biomedical Research and Innovation (FBRI), and RIKEN announced a research collaboration to develop new treatments for retinal diseases such as age-related macular degeneration and retinitis pigmentosa.

Further Key Findings From the Report Suggest:

Antiallergy is the largest segment owing to the increasing incidence of ocular infections, high prescription rate of antiallergy agents, and presence of a wide product portfolio

Retinal disorders segment dominated the market in 2016 due to increasing prevalence of age-related macular degenerations and diabetic retinopathy, its subtypes

The eye drops segment is anticipated to dominate the market in 2016. It is considered as the most preferred dosage form due to associated benefits such as easy assimilation, target-specific action, and faster recovery

Over-the-Counter (OTC) held the largest share in 2016 due to its low cost and increasing preference of OTC over prescription drugs

North America dominated the market in 2016 owing to factors such as the increase in demand for ophthalmic solutions for the treatment of glaucoma and dry eyes in this region.

Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to rising disposable income, presence of a large population base, and growing awareness programs by various organizations.

Some of the key players in this industry are Allergan; Aerie Pharmaceuticals, Inc.; Pfizer Inc.; Valeant Pharmaceuticals International, Inc.; Bayer AG; Genentech, Inc.; Novartis AG; Regeneron Pharmaceuticals, Inc.; Shire; and Santen Pharmaceutical Co., Ltd.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
  • 1.2 Research Methodology
  • 1.3 Geographic scope & assumptions
  • 1.4 Region-wise market calculation
    • 1.4.1 Region-wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
  • 1.5 Region-based segment share calculation
  • 1.6 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Ophthalmic Drug Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing incidence and prevalence of eye related disorders
      • 3.1.1.2 Increasing R&D pertaining to the development of novel drugs
      • 3.1.1.3 Presence of strong emerging pipeline drugs
      • 3.1.1.4 Increased funding from both public and private research organizations
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Loss of patent protection for blockbuster drugs
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Ophthalmic Drug - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Ophthalmic Drug Market: Drug class Estimates & Trend Analysis

  • 4.1 Ophthalmic drug market: Drug Class Movement Analysis
  • 4.2 Anti-Allergy
    • 4.2.1 Anti-Allergy market, 2014 - 2025 (USD Million)
  • 4.3 Anti-VEGF (Vascular Endothelial Growth Factor) agents
    • 4.3.1 Anti-VEGF agents, 2014 - 2025 (USD Million)
  • 4.4 Anti-inflammatory
    • 4.4.1 Anti-inflammatory market 2014 - 2025 (USD Million)
    • 4.4.2 Non-steroidal drugs
      • 4.4.2.1 Non-steroidal market drugs 2014 - 2025 (USD Million)
    • 4.4.3 Steroidal drugs
      • 4.4.3.1 Steroidal drugs market 2014 - 2025 (USD Million)
  • 4.5 Anti-glaucoma
    • 4.5.1 Anti-glaucoma 2014 - 2025 (USD Million)
  • 4.6 Others
    • 4.6.1 Others 2014 - 2025 (USD Million)

Chapter 5 Ophthalmic Drug Market: Disease Estimates & Trend Analysis

  • 5.1 Ophthalmic drug market: Disease type movement analysis
  • 5.2 Dry Eye
    • 5.2.1 Retasis
    • 5.2.2 Refresh
    • 5.2.3 Hyalein
    • 5.2.4 Diquas
    • 5.2.5 Dry Eye market, 2014 - 2025 (USD Million)
  • 5.3 Allergies
    • 5.3.1 Allergies, 2014 - 2025 (USD Million)
  • 5.4 Glaucoma
    • 5.4.1 Ganford
    • 5.4.2 Travatan/ travatan Z
    • 5.4.3 Glaucoma, 2014 - 2025 (USD Million)
  • 5.5 Inflammation/ Infection
    • 5.5.1 Inflammation/ Infection, 2014 - 2025 (USD Million)
  • 5.6 Retinal Disorders
    • 5.6.1 Lucentis
    • 5.6.2 Eylea
    • 5.6.3 Avastin
    • 5.6.4 Retinal Disorders, 2014 - 2025 (USD Million)
  • 5.7 Uveitis
    • 5.7.1 Uveitis 2014 - 2025 (USD Million)
  • 5.8 Others
    • 5.8.1 Others, 2014 - 2025 (USD Million)

Chapter 6 Ophthalmic Drug Market: Dosage form Estimates & Trend Analysis

  • 6.1 Ophthalmic drug market: Dosage movement analysis
  • 6.2 Gels
    • 6.2.1 Gels market, 2014 - 2025 (USD Million)
  • 6.3 Eye solutions
    • 6.3.1 Eye solutions, 2014 - 2025 (USD Million)
  • 6.4 Capsules & Tablets,
    • 6.4.1 Capsules & tablets, 2014 - 2025 (USD Million)
  • 6.5 Eye drops
    • 6.5.1 Eye drops, 2014 - 2025 (USD Million)
  • 6.6 Ointments
    • 6.6.1 Ointments, 2014 - 2025 (USD Million)

Chapter 7 Ophthalmic Drug Market: Product Estimates & Trend Analysis

  • 7.1 Ophthalmic drug market: Product movement analysis
  • 7.2 Prescription Drugs
    • 7.2.1 Prescription Drugs market, 2014 - 2025 (USD Million)
  • 7.3 OTC Drugs
    • 7.3.1 OTC Drugs, 2014 - 2025 (USD Million)
  • 7.4 Recent Drug Approval: 2000-2017

Chapter 8 Ophthalmic Drug Market: Regional Estimates & Trend Analysis, by Test Type

  • 8.1 Ophthalmic drug market share by region, 2016 & 2025
  • 8.2 North America
    • 8.2.1 North America ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.2.2 U.S
      • 8.2.2.1 U.S ophthalmic drugs market, 2014 - 2025 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Canada ophthalmic drug market, 2014 - 2025 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.3.2 UK
      • 8.3.2.1 UK ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.3.3 Germany
      • 8.3.3.1 Germany ophthalmic drug market, 2014 - 2025 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Japan ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 China ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 India ophthalmic drug market, 2014 - 2025 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil ophthalmic drug market, 2014 - 2025 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Mexico ophthalmic drug market, 2014 - 2025 (USD Million)
  • 8.6 MEA
    • 8.6.1 MEA ophthalmic drug, 2014 - 2025 (USD Million)
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa ophthalmic drug market, 2014 - 2025 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Strategy framework
  • 9.2 Market participation categorization
  • 9.3 Company Profiles
    • 9.3.1 Alcon
      • 9.3.1.1 Company Overview
      • 9.3.1.2 Financial Performance
      • 9.3.1.3 Product benchmarking
      • 9.3.1.4 Geographic Footprint
      • 9.3.1.5 Strategic Initiatives
    • 9.3.2 Johnson and Johnson Vision Care, Inc.
      • 9.3.2.1 Company Overview
      • 9.3.2.2 Financial Performance
      • 9.3.2.3 Product Benchmarking
      • 9.3.2.4 Geographic Footprint
      • 9.3.2.5 Strategic Initiatives
    • 9.3.3 Bausch & Lomb Incorporated
      • 9.3.3.1 Company overview
      • 9.3.3.2 Financial Performance
      • 9.3.3.3 Product Benchmarking
      • 9.3.3.4 Strategic Initiatives
    • 9.3.4 Novartis AG
      • 9.3.4.1 Company Overview
      • 9.3.4.2 Financial Performance
      • 9.3.4.3 Product Benchmarking
      • 9.3.4.4 Geographic Footprint
      • 9.3.4.5 Strategic Initiatives
    • 9.3.5 Merck Sharp & Dohme Corp.
      • 9.3.5.1 Company overview
      • 9.3.5.2 Financial Performance
      • 9.3.5.3 Product benchmarking
      • 9.3.5.4 Geographic Footprint
      • 9.3.5.5 Strategic Initiatives
    • 9.3.6 Regeneron Pharmaceuticals Inc.
      • 9.3.6.1 Company Overview
      • 9.3.6.2 Financial Performance
      • 9.3.6.3 Product Benchmarking
      • 9.3.6.4 Strategic Initiatives
    • 9.3.7 Allergan
      • 9.3.7.1 Company Overview
      • 9.3.7.2 Financial Performance
      • 9.3.7.3 Product Benchmarking
      • 9.3.7.4 Strategic Initiatives
    • 9.3.8 Pfizer Inc.
      • 9.3.8.1 Company Overview
      • 9.3.8.2 Financial Performance
      • 9.3.8.3 Product Benchmarking
      • 9.3.8.4 Strategic Initiatives
    • 9.3.9 Valeant
      • 9.3.9.1 Company Overview
      • 9.3.9.2 Financial Performance
      • 9.3.9.3 Product Benchmarking
      • 9.3.9.4 Strategic Initiatives
    • 9.3.10 Bayer AG
      • 9.3.10.1 Company Overview
      • 9.3.10.2 Financial Performance
      • 9.3.10.3 Product Benchmarking
      • 9.3.10.4 Strategic Initiatives
    • 9.3.11 Santen Pharmaceuticals Co. Ltd
      • 9.3.11.1 Company Overview
      • 9.3.11.2 Financial Performance
      • 9.3.11.3 Product Benchmarking
      • 9.3.11.4 Strategic Initiatives
    • 9.3.12 Genentech, Inc.
      • 9.3.12.1 Company Overview
      • 9.3.12.2 Financial Performance
      • 9.3.12.3 Product Benchmarking
      • 9.3.12.4 Geographic Footprint
      • 9.3.12.5 Strategic Initiatives

Chapter 10 Primary Research Analysis

  • 10.1 Factors estimated to impact on market growth
  • 10.2 Market scenario
  • 10.3 Key KoL responses

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 Phase 3: Ophthalmic Pipeline drugs
  • TABLE 3 List of antiallergy (Eye drops)
  • TABLE 4 Nonsteroidal- anti-inflammatories
  • TABLE 5 Corticosteroids drugs
  • TABLE 6 Antiglaucoma drugs
  • TABLE 7 Artificial Tears- Dry Eye
  • TABLE 8 North America ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 9 North America ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 10 North America ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 11 North America ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 12 North America ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 13 U.S. ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 14 U.S. ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 15 U.S. ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 16 U.S. ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 17 U.S. ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 18 Canada ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 19 Canada ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 20 Canada ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 21 Canada ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 22 Canada ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 23 Europe ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 24 Europe ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 25 Europe ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 26 Europe ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 27 Europe ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 28 UK ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 29 UK ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 30 UK ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 31 UK ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 32 UK ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 33 Germany ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 34 Germany ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 35 Germany ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 36 Germany ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 37 Germany ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 38 Asia pacific ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 39 Asia pacific ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 40 Asia pacific ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 41 Asia pacific ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 42 Asia pacific ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 43 Japan ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 44 Japan ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 45 Japan ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 46 Japan ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 47 Japan ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 48 China ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 49 China ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 50 China ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 51 China ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 52 China ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 53 India ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 54 India ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 55 India ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 56 India ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 57 India ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 58 Latin America ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 59 Latin America ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 60 Latin America ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 61 Latin America ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 62 Latin America ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 63 Brazil ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 64 Brazil ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 65 Brazil ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 66 Brazil ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 67 Brazil ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 68 Mexico ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 69 Mexico ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 70 Mexico ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 71 Mexico ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 72 Mexico ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 73 MEA ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 74 MEA ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 75 MEA ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 76 MEA ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 77 MEA ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 78 South Africa ophthalmic drug market, by drug class, 2014 - 2025, revenue (USD Million)
  • TABLE 79 South Africa ophthalmic drug market, by anti-inflammatory, 2014 - 2025, by revenue (USD Million)
  • TABLE 80 South Africa ophthalmic drug market, by disease, 2014 - 2025, by revenue (USD Million)
  • TABLE 81 South Africa ophthalmic drug market, by dosage form, 2014 - 2025, by revenue (USD Million)
  • TABLE 82 South Africa ophthalmic drug market, by product, 2014 - 2025, by revenue (USD Million)
  • TABLE 83 Company Analysis

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Value chain based sizing & forecasting
  • FIG. 4 QFD modelling for market share assessment
  • FIG. 5 Market summary, 2016
  • FIG. 6 Market trends & outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market driver relevance analysis (Current & future impact)
  • FIG. 9 R&D Spending's (2015- 16)
  • FIG. 10 Market restrain relevance analysis (Current & future impact)
  • FIG. 11 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 12 Porter's Five Forces Analysis
  • FIG. 13 Ophthalmic drug market type outlook key takeaways
  • FIG. 14 Ophthalmic drug market: Drug class movement analysis
  • FIG. 15 Anti-Allergy market, 2014 - 2025 (USD Million)
  • FIG. 16 Anti-VEGF agents market, 2014 - 2025 (USD Million)
  • FIG. 17 Anti-inflammatory market, 2014 - 2025 (USD Million)
  • FIG. 18 Non-steroidal drugs market, 2014 - 2025 (USD Million)
  • FIG. 19 Steroidal drugs market, 2014 - 2025 (USD Million)
  • FIG. 20 Anti-glaucoma market, 2014 - 2025 (USD Million)
  • FIG. 21 Other market, 2014 - 2025 (USD Million)
  • FIG. 22 Ophthalmic drug market technology outlook key takeaways
  • FIG. 23 Ophthalmic drug: Disease type movement analysis
  • FIG. 24 Dry Eye, 2014 - 2025 (USD Million)
  • FIG. 25 Allergies market, 2014 - 2025 (USD Million)
  • FIG. 26 Glaucoma market, 2014 - 2025 (USD Million)
  • FIG. 27 Inflammation/ Infection market, 2014 - 2025 (USD Million)
  • FIG. 28 Retinal Disorders market, 2014 - 2025 (USD Million)
  • FIG. 29 Uveitis market, 2014 - 2025 (USD Million)
  • FIG. 30 Others market, 2014 - 2025 (USD Million)
  • FIG. 31 Ophthalmic drug market application outlook key takeaways
  • FIG. 32 Ophthalmic drug: Dosage movement analysis
  • FIG. 33 Gels, 2014 - 2025 (USD Million)
  • FIG. 34 Eye solutions market, 2014 - 2025 (USD Million)
  • FIG. 35 Capsules & tablets market, 2014 - 2025 (USD Million)
  • FIG. 36 Eye drops market, 2014 - 2025 (USD Million)
  • FIG. 37 Ointment market, 2014 - 2025 (USD Million)
  • FIG. 38 Ophthalmic drug market product outlook key takeaways
  • FIG. 39 Ophthalmic drug: Product movement analysis
  • FIG. 40 Prescription Drugs, 2014 - 2025 (USD Million)
  • FIG. 41 OTC Drugs market, 2014 - 2025 (USD Million)
  • FIG. 42 Regional market place: Key takeaways
  • FIG. 43 Regional outlook, 2016 & 2025
  • FIG. 44 North America ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 45 U.S. ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 46 Canada ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 47 Europe ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 48 UK ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 49 Germany ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 50 Asia Pacific ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 51 Japan ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 52 China ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 53 India ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 54 Latin America ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 55 Brazil ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 56 Mexico ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 57 MEA ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 58 South Africa ophthalmic drug market, 2014 - 2025 (USD Million)
  • FIG. 59 Strategy framework
  • FIG. 60 Participant categorization
  • FIG. 61 Factors estimated to impact on market growth
Back to Top